CD3 binding antibodies
US11421027B2 · kind B2 · utility
3Cited by
19References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2021 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Oct 1, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.